AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6122463
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg slow release oxprenolol with 0.25 mg cyclopenthiazide
Trial: 30943910
Drug: Antenatal corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal corticosteroids (betamethasone 12 mg, 3 mL intramuscularly)
Trial: 30943910
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline 3 mL IM)
Trial: 26926544
Drug: Surgical section
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical section of the filum plus medical treatment
Trial: 18973910
Drug: Combined stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined stimulating surface projection zone of decussation of pyramid and traditional acupuncture treatment
Trial: 18973910
Drug: Traditional acupuncture
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional acupuncture treatment only
Trial: 15527071
Drug: Fructose administration
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose administration
Trial: 31870702
Drug: Sucrose administration
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose administration
Trial: 30075491
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg oral tablets
Trial: 17892999
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea (3 glasses daily for 6 months)
Trial: 17892999
Drug: Water (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (control group, 3 glasses daily for 6 months)
Trial: 14706203
Drug: Propofol treatment
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol treatment
Trial: 31313547
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg once daily for 4 months along with erythropoietin 6000 IU S/C and IV iron 100 mg twice weekly after each hemodialysis
Trial: 31313547
Drug: Erythropoietin 6000
RxNorm normalized name: ERYTHROPOIETIN
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin 6000 IU S/C and IV iron 100 mg twice weekly after each hemodialysis without atorvastatin for 4 months
Trial: 27928454
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium bicarbonate supplementation (interdialytic doses)
Trial: 27928454
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oral sodium bicarbonate supplementation, higher bicarbonate prescriptions in dialysis)
Trial: 27965790
Drug: Intradialytic oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradialytic oral nutritional supplement (ONS)
Trial: 20384749
Drug: Low-fluence Q-switched
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fluence Q-switched Nd:YAG laser after 8 weeks of topical TC treatment
Trial: 20384749
Drug: Topical triple
RxNorm normalized name: Triple Paste Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical triple combination (TC) cream
Trial: 17941095
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) psychoeducational workshop
Trial: 12590619
Drug: Sedating antidepressants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedating antidepressants (amitriptyline, imipramine, doxepin, mianserin)
Trial: 12590619
Drug: Nocturnal doses
RxNorm normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nocturnal doses of sedating antidepressants (dothiepin, mianserin, mirtazapine)
Trial: 12590619
Drug: Nonsedating antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsedating antidepressants (moclobemide, fluoxetine, paroxetine, venlafaxine, nefazodone)
Trial: 12590619
Drug: Combinations of
RxNorm normalized name: Combinations of vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combinations of nonsedating antidepressants and benzodiazepines
Trial: 12590619
Drug: Antidepressants in
RxNorm normalized name: Other antidepressants in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants in clinical trials
Trial: 10683095
Drug: Control drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drink (0.8 g x kg(‐1) body weight of glucose)
Trial: 10683095
Drug: Glutamine drink
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine drink (0.8 g x kg(‐1) body weight of glucose + 0.3 g x kg(‐1) body weight of glutamine)
Trial: 10683095
Drug: Wheat hydrolysate
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat hydrolysate drink (0.8 g x kg(‐1) body weight of glucose + 0.3 g x kg(‐1) body weight of wheat hydrolysate)
Trial: 10683095
Drug: Whey hydrolysate
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey hydrolysate drink (0.8 g x kg(‐1) body weight of glucose + 0.3 g x kg(‐1) body weight of whey hydrolysate)
Trial: 8692117
Drug: Bolus 5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus 5‐FU 600 mg/m2 plus folinic acid 300 mg/m2 day 2 to 4 with or without dipyridamole 3 x 75 mg p.o. day 1 to 5
Trial: 8692117
Drug: Bolus 5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus 5‐FU 300 to 350 mg/m2, folinic acid 200 mg/m2 and interferon 5 x 10(9) U/m2 s.c. day 1 to 5
Trial: 8692117
Drug: PALA 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PALA 250 mg/m2, MTX 250 mg/m2 day 1 and bolus FU 600 mg/m2 day 2 q day 14
Trial: 8692117
Drug: FU 2.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FU 2.6 g/m2 given as 24‐h infusion plus interferon 3 x 10(9) Ul s.c.
Trial: 8692117
Drug: FU 2.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FU 2.6 g/m2 given as 24‐h infusion, folinic acid 500 mg/m2 as 2‐h infusion with or without interferon 3 x 10(9) U s.c.
Trial: 8692117
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion regimens
Trial: 1531467
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional drugs after general anesthesia (controls)
Trial: 23281758
Drug: L-threonine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-threonine supplementation at 0.2%
Trial: 23281758
Drug: L-threonine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-threonine supplementation at 0.3%
Trial: 23281758
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0% L-threonine)
Trial: 19624730
Drug: Topical cream
RxNorm normalized name: Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream with Bifidobacterium longum lysate at 10% (n = 33)
Trial: 19624730
Drug: Control cream
RxNorm normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control cream (n = 33)
Trial: 19624730
Drug: Topical cream
RxNorm normalized name: Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream with Bifidobacterium longum lysate at 10%
Trial: 11378052
Drug: Pentosan polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan polysulfate sodium (PPS) at doses of 300 mg, 600 mg, and 900 mg daily
Trial: 18370544
Drug: Atenolol 50mg
RxNorm normalized name: ATENOLOL 50MG TAB
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 50mg daily
Trial: 18370544
Drug: Perindopril 4mg
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perindopril 4mg daily
Trial: 18211932
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin 400 mg
Trial: 8157551
Drug: Intravenous ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ofloxacin 400 mg
Trial: 3410937
Drug: GH (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH (0.15 U/kg, sc, three times weekly)
Trial: 3410937
Drug: GH (0.09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH (0.09 U/kg, three times weekly)
Trial: 3410937
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with EE2 (50 ng/kg.day) and GH (0.09 U/kg, three times weekly)
Trial: 3410937
Drug: GH (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH (0.15 U/kg, three times weekly) with EE2 (100 ng/kg.day)
Trial: 29071946
Drug: Electroacupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture plus western medicine
Trial: 29071946
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine only (Control)
Trial: 21983111
Drug: Clopidogrel and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel and Aspirin (C+A)
Trial: 17599602
Drug: Recombinant nematode
RxNorm normalized name: Recombinant nematode anticoagulant protein-2
DrugBank: Anpocogin (DB06552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant nematode anticoagulant protein c2 (rNAPc2) administered intravenously every 48 hours for a total of 1 to 3 doses (1.5 to 10 microg/kg)
Trial: 17599602
Drug: Higher-dose rNAPc2
RxNorm normalized name: rNAPc2
DrugBank: Anpocogin (DB06552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose rNAPc2 (≥7.5 microg/kg)
Trial: 17599602
Drug: Half-dose UFH
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose UFH
Trial: 2150640
Drug: Isradipine 2.5
RxNorm normalized name: isradipine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 2.5 to 5.0mg twice daily
Trial: 2150640
Drug: Hydrochlorothiazide 12.5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 to 25mg twice daily
Trial: 28627376
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose inhaler with AeroChamber‐MV (MDI‐AC)
Trial: 22075163
Drug: Family Focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Focused Grief Therapy (FFGT) Model
Trial: 15347773
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (600 mg twice daily for 3 months)
Trial: 31111045
Drug: Routine postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine postoperative anti-inflammatory treatment (Cohort I)
Trial: 31111045
Drug: Preoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative treatment (warming compress, lid hygiene, and anti-inflammatory treatment) and routine postoperative anti-inflammatory treatment (Cohort II)
Trial: 31111045
Drug: Enhanced postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced postoperative anti-inflammatory treatment (Cohort III)
Trial: 15156004
Drug: Clopidogrel pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel pre-treatment (75 mg x 2 daily at least 48 hours before intervention)
Trial: 15156004
Drug: Clopidogrel loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel loading dose (300 mg at intervention time)
Trial: 31596061
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine with a loading dose of 1 μg/kg body weight followed by 0.2 μg/kg body weight/hour via continuous infusion
Trial: 31596061
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 2 mg/kg body weight with atropine 0.01 mg/kg body weight
Trial: 28129985
Drug: Pitolisant (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitolisant (5 mg, 10 mg, 20 mg, or 40 mg once daily)
Trial: 23884072
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with pegylated interferon (peg‐IFN) alfa‐2a plus self‐administered ribavirin (RBV)
Trial: 23884072
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment with pegylated interferon (peg‐IFN) alfa‐2a plus self‐administered ribavirin (RBV)
Trial: 23884072
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment (among those who received it)
Trial: 23884072
Drug: Overall participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall participants who received at least 1 dose of study medication
Trial: 20506504
Drug: Colposcopically directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colposcopically directed biopsies taken within 6 months of definitive therapy
Trial: 19434697
Drug: Stapler combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stapler combined with seromuscular patch
Trial: 16479752
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded tapered implants with single provisional crowns at surgery and definitive crowns 8 weeks later
Trial: 16479752
Drug: Conventional 2-stage
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional 2-stage implants
Trial: 1526265
Drug: 1 microgram
RxNorm normalized name: Alfacalcidol 1 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microgram of alphacalcidol daily for 4 months
Trial: 3903813
Drug: Open drug
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open drug (DL-phenylalanine)
Trial: 3903813
Drug: L-phenylalanine
RxNorm normalized name: L-Phenylalanine
DrugBank: Phenylalanine (DB00120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-phenylalanine
Trial: 29132842
Drug: 3.3% glucose/saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.3% glucose/saline (51mEq/L sodium and 33g/L glucose)
Trial: 29132842
Drug: 5% glucose/saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose/saline (154mEq/L sodium and 50g/L glucose)
Trial: 24868587
Drug: Interdisciplinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary treatment (experimental group)
Trial: 24868587
Drug: Standard pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacological therapy (control group)
Trial: 12358339
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) only (group C)
Trial: 7863760
Drug: Intravenous cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefuroxime (3 g infused in 15-25 min in preliminary study, 3 g infused in 15 min in main study)
Trial: 1778193
Drug: Nisoldipine 5
RxNorm normalized name: nisoldipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 5 mg twice a day
Trial: 3691593
Drug: Nisoldipine 10
RxNorm normalized name: nisoldipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 10 mg daily
Trial: 31529663
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of autologous bone marrow mononuclear cells (MNCs) at a target dose of 10 million cells per kilogram, administered within 24-72 hours of stroke onset.
Trial: 31529663
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of autologous bone marrow mononuclear cells (MNCs)
Trial: 26373634
Drug: Mindfulness Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness Based Cognitive Therapy (MBCT) in addition to treatment as usual (TAU)
Trial: 21242584
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream (IMQ) once daily, 5 days/week for 6 weeks
Trial: 19568709
Drug: Rhodiola-Gingko Capsule
RxNorm normalized name: RHODIOLA ROSEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhodiola-Gingko Capsule (RGC), 270 mg herbal extracts, 4 capsules per day for 7 weeks
Trial: 17353578
Drug: Regular red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular red wine (250 ml)
Trial: 17353578
Drug: Dealcoholized red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dealcoholized red wine (250 ml)
Trial: 14753131
Drug: CHOP chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHOP chemotherapy in routine clinical practice (RCP)
Trial: 11491635
Drug: Penicillin (28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin (28 capsules of 500 mg taken every 6 hours for 7 days)
Trial: 16809258
Drug: Epidural anaesthesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural anaesthesia (EDA) with ropivacaine + paracetamol (4 x 1 g tablet) + injected or oral morphine on demand
Trial: 16809258
Drug: Oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone hydrochloride (2 x 10 mg tablet) + paracetamol (4 x 1 g tablet) + injected or oral morphine on demand
Trial: 10566625
Drug: DHEA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA supplementation (50 mg/day for 3 months)
Trial: 6688799
Drug: Pirenzepine 50
RxNorm normalized name: pirenzepine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 50 mg per os daily for 6 months
Trial: 6688799
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg per os daily for 6 months
Trial: 6688799
Drug: Topical antacids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antacids as needed for 6 months
Trial: 29383606
Drug: Indigo carmine
RxNorm normalized name: indigo carmine
DrugBank: Indigotindisulfonic acid (DB11577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indigo carmine mixed solution
Trial: 27378823
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg bid 24 h prior to ascent
Trial: 20193645
Drug: Agomelatine 25
RxNorm normalized name: Agomelatine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine 25 to 50 mg
Trial: 20193645
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 to 100 mg
Trial: 18923706
Drug: Tribendimidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribendimidine (200 mg for children, 400 mg for adults)
Trial: 18923706
Drug: Albendazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (200 mg for children, 400 mg for adults)
Trial: 16168630
Drug: Alprazolam 1.00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 1.00 mg
Trial: 23932198
Drug: Intra-articular tenoxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular tenoxicam injection (20 mg)
Trial: 23932198
Drug: Arthrocentesis plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocentesis plus sodium hyaluronate injection
Trial: 22341892
Drug: Continuous ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ropivacaine wound infusion
Trial: 22341892
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine with saline wound infusion
Trial: 22341892
Drug: Saline wound
RxNorm normalized name: GNP Saline Wound Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline wound infusion
Trial: 20651413
Drug: Aquatic exercise
RxNorm normalized name: Mentha aquatica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic exercise and education (AE; aquatic exercise twice a week with once-a-week group education)
Trial: 20859682
Drug: Control-concentrate (CC)
RxNorm normalized name: CC-90001
DrugBank: CC-90001 (DB18445)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control-concentrate (CC) group received 1.0 times their maintenance requirements.
Trial: 8109939
Drug: M500 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M500 tablet formulation (500 mg)
Trial: 8109939
Drug: M250 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M250 tablet formulation (500 mg)
Trial: 8109939
Drug: Clinical-trial formulation
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical-trial formulation (500 mg)
Trial: 8109939
Drug: Syrup formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup formulation (500 mg) with food
Trial: 8109939
Drug: Syrup formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup formulation (500 mg) fasting